TAKNYSE

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Healthcare·Oncology·Commercial·Tokyo, Japan
OncologyRare DiseaseNeurologyImmunologyCardiovascularInfectious DiseaseRespiratoryPainDermatologyHematologyNephrologyGastroenterologyReproductivePsychiatry

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK): 150 pipeline candidates · 22 upcoming catalysts · 52 clinical trials. Updated within the last hour.

9.2/10

BioSniper Score

4-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health8.4

D/E 1.05 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth10.0

150 candidates

Catalyst Momentum10.0

22 upcoming, next in ~5d

Insider SignalN/A

N/A

A transparent, data-derived signal for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$49.0B

Cash

$233.7B

Quarterly Burn

—

Runway

—

Revenue

—

Cash Runway vs Catalysts

Upcoming catalyst timeline.

Today~23 mo out
Catalyst within runway

Pipeline (150 candidates)

DrugPhase
[^11c]t-773Phase 1
[14c] subasumstatPhase 1
0.4% zoc2017217Phase 2
adalimumabPhase 4
advatePhase 3
adynovatePhase 3
alectinibPhase 4
amphotericin b liposome for injection (strength—
amphotericin b liposome for injection (trade name—
azilsartanPhase 3

Showing 10 of 150 candidates. Sign up for full pipeline.

Upcoming Catalysts (22)

Phase2_StartPhase 2 Start: A Phase 2 Open-label Trial to Evaluate the Efficacy and Safety of Rusfertide in Japanese Patients Wi

Clinical data readout — efficacy/safety results are a high-impact catalyst.

36.4% historical Phase 2 primary-endpoint success rate (n=228)

Phase2_StartPhase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety an

Clinical data readout — efficacy/safety results are a high-impact catalyst.

36.4% historical Phase 2 primary-endpoint success rate (n=228)

Phase3_ToplinePhase 3 Topline: An Open-label, Multicenter Clinical Study on The Long-term Safety and Efficacy of Multiple Treatment

Clinical data readout — efficacy/safety results are a high-impact catalyst.

68.6% historical Phase 3 primary-endpoint success rate (n=363)

Phase3_ToplinePhase 3 Topline: An Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous (

Clinical data readout — efficacy/safety results are a high-impact catalyst.

68.6% historical Phase 3 primary-endpoint success rate (n=363)

Phase3_ToplinePhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mez

Clinical data readout — efficacy/safety results are a high-impact catalyst.

68.6% historical Phase 3 primary-endpoint success rate (n=363)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

356

Total value held

$1.39B

HolderSharesValue
fmr llc7,117,486$131.8M
morgan stanley6,469,600$119.8M
adage capital partners gp, l.l.c.6,424,984$119.0M
goldman sachs group inc5,618,728$104.1M
brandes investment partners, lp4,430,642$82.1M
blackrock, inc.3,176,421$58.8M
arrowstreet capital, limited partnership3,116,311$57.7M
renaissance technologies llc2,989,100$55.4M
d. e. shaw & co., inc.2,602,543$48.2M
citadel advisors llc2,166,460$40.1M

Showing top 10 of 356 institutional holders of Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock). Sign up for the full 13F holder list and quarter-by-quarter ownership history.

52 clinical trials·CEO: Mr. Christophe P. Weber

Frequently asked questions

How many drug candidates are in Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s pipeline?

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) has 150 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s lead drug candidate?

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s most advanced tracked candidate is [^11c]t-773 (Phase 1) for Healthy Volunteers.

What is Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s next catalyst?

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2 Open-label Trial to Evaluate the Efficacy and Safety of Rusfertide in Japanese Patients Wi" — expected June 23, 2026.

What is Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market capitalization?

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market capitalization is approximately $49.0B.

Who is the CEO of Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)?

Mr. Christophe P. Weber is the chief executive officer of Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK).

Get the full picture on Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar